Revumenib Clinical Trials (2026): 19 Studies for Acute Myeloid Leukemia & Acute Lymphoblastic Leukemia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
19 Revumenib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 14 indications (including Acute Myeloid Leukemia & Acute Lymphoblastic Leukemia) and 1,750 total planned enrollment. 2 Phase 3 Revumenib trials and 2 Phase 2 are listed. 12 Revumenib clinical trials are actively recruiting at 60 U.S. sites across 22 states. Most recent activity: NCT07283640 (Aug 2031).
Where to Participate: All Revumenib Trial Sites in the U.S. (60 sites across 22 states)
Every actively recruiting Revumenibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | City of Hope Medical Center | Duarte91010 | NCT06575296 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT05886049 | Map |
| CA | Rady Children's Hospital | San Diego92132 | NCT06177067 | Map |
| CO | Children's Hospital Colorado | Aurora80045 | NCT06177067 | Map |
| CO | University of Colorado | Aurora80045 | NCT04065399 | Map |
| CT | Yale Cancer Center | New Haven06150 | NCT06313437 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Aventura | Aventura33180 | NCT05886049 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT05886049 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT05886049 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT05886049 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT05886049 | Map |
| GA | Children's Healthcare of Atlanta | Atlanta30329 | NCT06177067 | Map |
| GA | Emory Winship Cancer Institute | Atlanta30322 | NCT04065399 | Map |
| IL | The University of Chicago Medical Center | Chicago60637 | NCT04065399 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05886049 | Map |
| IA | University of Iowa Hospital | Iowa City52246 | NCT04065399 | Map |
| KS | University of Kansas Clinical Research Center | Fairway66205 | NCT05886049 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT05886049 | Map |
| KS | University of Kansas Hospital-Indian Creek Campus | Overland Park66211 | NCT05886049 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT05886049 | Map |
| MD | Johns Hopkins University | Baltimore21218 | NCT06284486 | Map |
| MD | University of Maryland/Greenebaum Cancer Center | Baltimore21201 | NCT05886049 | Map |
| MA | Dana-Farber Cancer Center | Boston02215 | NCT06284486 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06313437 | Map |
| MO | Children's Mercy Hospital of Kansas City | Kansas City64108 | NCT06177067 | Map |
| MO | Washington University in St. Louis School of Medicine | St Louis63110 | NCT04065399 | Map |
| NJ | Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) | Basking Ridge07920 | NCT07356154 | Map |
| NJ | Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown07748 | NCT07356154 | Map |
| NJ | Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale07645 | NCT07356154 | Map |
| NY | Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities) | Commack11725 | NCT07356154 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT07356154 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06229912 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06284486 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT07356154 | Map |
| NY | Memorial Sloan- Kettering Cancer Center | New York10065 | NCT06177067 | Map |
| NY | Montefiore Medical Center | New York10467 | NCT04065399 | Map |
| NY | Memorial Sloan Kettering Nassau (All Protocol Activities) | Rockville Centre11553 | NCT07356154 | Map |
| NC | UNC Hospitals, University of North Carolina at Chapel Hill | Chapel Hill24514 | NCT06222580 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT05886049 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT05886049 | Map |
| NC | Duke University Medical Center | Durham27110 | NCT04065399 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT05886049 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT06177067 | Map |
| OH | University of Cincinnati Cancer Center-UC Medical Center | Cincinnati45219 | NCT05886049 | Map |
| OH | Ohio State University | Columbus43201 | NCT04065399 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05886049 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06222580 | Map |
| OH | University of Cincinnati Cancer Center-West Chester | West Chester45069 | NCT05886049 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05886049 | Map |
| OR | Oregon Health & Science University | Portland97239 | NCT04065399 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT06177067 | Map |
| PA | University of Pennsylvania | Philadelphia19104 | NCT04065399 | Map |
| PA | University of Pennsylvania | Philadelphia19104 | NCT06222580 | Map |
| TN | St. Jude Children's Research Hospital | Memphis38105 | NCT06177067 | Map |
| TX | UT Southwestern/Simmons Cancer Center | Dallas75390 | NCT06177067 | Map |
| TX | Cook Children's Medical Center | Fort Worth76104 | NCT06177067 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06229912 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06284486 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05886049 | Map |
| WI | University of Wisconsin Carbone Cancer Center | Madison53792 | NCT06222580 | Map |
Revumenib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | withdrawn | not yet recruiting | no longer available | Total |
|---|---|---|---|---|---|---|---|
| P1 | 5 | 2 | 2 | 1 | 10 | ||
| P1/P2 | 3 | 1 | 4 | ||||
| P2 | 1 | 1 | 2 | ||||
| P3 | 2 | 2 | |||||
| N/A | 1 | 1 |
Recruiting Revumenib clinical trials (12)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07283640 | A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia | P1 | Blinatumomab | 20 | May 2026 |
| NCT06652438 | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML | P3 | Acute Myeloid Leukemia, Adult | 415 | Mar 2025 |
| NCT07211958 | REVEAL-ND NPM1Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation | P3 | Acute Myeloid Leukemias | 468 | Nov 2025 |
| NCT07356154 | A Study of Revumenib and Mezigdomide in People With Leukemia | P1/P2 | Leukemia | 52 | Jan 2026 |
| NCT06284486 | A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | P1/P2 | Acute Myeloid Leukemia | 8 | Sep 2024 |
| NCT06229912 | A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes | P2 | Leukemia | 40 | Jun 2024 |
| NCT06575296 | Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant | P1 | Acute Leukemia | 27 | Dec 2024 |
| NCT06313437 | Revumenib in Combination With 7+3 + Midostaurin in AML | P1 | Acute Myeloid Leukemia | 22 | Dec 2024 |
| NCT05886049 | A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease | P1 | Acute Myeloid Leukemia | 38 | Jun 2024 |
| NCT04065399 | AUGMENT-101A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | P1/P2 | Acute Myeloid Leukemia | 447 | Nov 2019 |
| NCT06177067 | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | P1 | Refractory Acute Myeloid Leukemia | 24 | Apr 2024 |
| NCT06222580 | SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation | P1 | Acute Myeloid Leukemia With FLT3/ITD Mutation | 30 | Feb 2024 |
Revumenib clinical trials by indication
Acute Myeloid Leukemia (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06284486 | — | P1/P2 | recruiting | A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib |
| NCT06313437 | — | P1 | recruiting | Revumenib in Combination With 7+3 + Midostaurin in AML |
| NCT05886049 | — | P1 | recruiting | A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease |
| NCT04065399 | AUGMENT-101 | P1/P2 | recruiting | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation |
Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07356154 | — | P1/P2 | recruiting | A Study of Revumenib and Mezigdomide in People With Leukemia |
| NCT06229912 | — | P2 | recruiting | A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes |
Acute Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06575296 | — | P1 | recruiting | Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant |
| NCT05406817 | — | P1 | completed | Study of Radiolabeled Revumenib in Adults With Acute Leukemia |
Pediatric Acute Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07052994 | GO | P1 | withdrawn | A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients |
Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07498465 | — | P1 | withdrawn | A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia |
Blinatumomab (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07283640 | — | P1 | not yet recruiting | A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia |
Acute Myeloid Leukemias (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07211958 | REVEAL-ND NPM1 | P3 | recruiting | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation |
Acute Myeloid Leukemia, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06652438 | — | P3 | recruiting | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML |
Refractory Acute Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06177067 | — | P1 | recruiting | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia |
Acute Myeloid Leukemia With FLT3/ITD Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06222580 | — | P1 | recruiting | SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation |
Recurrent Acute Leukemia of Ambiguous Lineage (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05761171 | — | P2 | active not recruiting | A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia |
Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05731947 | — | P1/P2 | completed | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors |
Relapsed/Refractory Leukemias (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05326516 | — | P1 | completed | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia |
Relapsed/Refractory Acute Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05918913 | — | N/A | no longer available | Expanded Access Program for Revumenib |
Revumenib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| REVEAL-ND NPM1 | NCT07211958 | P3 | recruiting | Acute Myeloid Leukemias | 468 | — |
Terminated and withdrawn Revumenib trials (2)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT07498465withdrawnA Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
- NCT07052994withdrawnA Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients
All Revumenib trials (19)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07283640 | A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia | P1 | not yet recruiting | 20 | M.D. Anderson Cancer Center | May 2026 | |
| NCT06652438 | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML | P3 | recruiting | 415 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Mar 2025 | |
| NCT07211958 | REVEAL-ND NPM1 | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation | P3 | recruiting | 468 | Syndax Pharmaceuticals | Nov 2025 |
| NCT07356154 | A Study of Revumenib and Mezigdomide in People With Leukemia | P1/P2 | recruiting | 52 | Memorial Sloan Kettering Cancer Center | Jan 2026 | |
| NCT06284486 | A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | P1/P2 | recruiting | 8 | M.D. Anderson Cancer Center | Sep 2024 | |
| NCT06229912 | A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes | P2 | recruiting | 40 | M.D. Anderson Cancer Center | Jun 2024 | |
| NCT07498465 | A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia | P1 | withdrawn | 0 | Children's Oncology Group | Sep 2026 | |
| NCT06575296 | Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant | P1 | recruiting | 27 | City of Hope Medical Center | Dec 2024 | |
| NCT06313437 | Revumenib in Combination With 7+3 + Midostaurin in AML | P1 | recruiting | 22 | Richard Stone, MD | Dec 2024 | |
| NCT05886049 | A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease | P1 | recruiting | 38 | National Cancer Institute (NCI) | Jun 2024 | |
| NCT05761171 | A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia | P2 | active not recruiting | 78 | Children's Oncology Group | Jan 2024 | |
| NCT04065399 | AUGMENT-101 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | P1/P2 | recruiting | 447 | Syndax Pharmaceuticals | Nov 2019 |
| NCT06177067 | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | P1 | recruiting | 24 | St. Jude Children's Research Hospital | Apr 2024 | |
| NCT06222580 | SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation | P1 | recruiting | 30 | Uma Borate | Feb 2024 | |
| NCT07052994 | GO | A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients | P1 | withdrawn | 0 | M.D. Anderson Cancer Center | May 2026 |
| NCT05731947 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | P1/P2 | completed | 42 | Syndax Pharmaceuticals | Apr 2023 | |
| NCT05406817 | Study of Radiolabeled Revumenib in Adults With Acute Leukemia | P1 | completed | 9 | Syndax Pharmaceuticals | Aug 2022 | |
| NCT05326516 | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | P1 | completed | 30 | Syndax Pharmaceuticals | Mar 2022 | |
| NCT05918913 | Expanded Access Program for Revumenib | — | no longer available | 0 | Syndax Pharmaceuticals | — |
Revumenib clinical trials: frequently asked questions
- How many Revumenib clinical trials are there?
- 19 Revumenib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 11 are actively recruiting participants. 3 are marked completed.
- Are Revumenib clinical trials recruiting in 2026?
- Yes — 11 Revumenib trials are actively recruiting in 2026, with 60 U.S. sites across 22 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Revumenib being studied for?
- Revumenib is being studied for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Leukemia and 45 more. The trials are grouped by indication on this page.
- What phase is Revumenib in?
- Revumenib clinical trials span 2 Phase 3, 2 Phase 2, 10 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Revumenib clinical trials?
- The lead sponsor across the most Revumenib trials is Syndax Pharmaceuticals, with 9 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Revumenibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: